Classe 5
Therapeutic preparations, namely, antibodies for use in targeting the C-C chemokine receptor type 5 [CCR5] cell receptortherapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, non-alcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19
Classe 42
Scientific research consulting services in the field of immunologyscientific research consulting services in the field of antibodies for use in targeting the CCR5 cell receptorscientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19medical research servicesmedical research services in the field of antibodies for use in targeting the CCR5 cell receptormedical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting
Classe 44
Providing medical information, via a websiteproviding information in the field of using antibodies for medical treatment, for use in targeting the CCR5 cell receptor, via a websiteproviding health and medical information, via a website, namely, providing information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting